Physician profile
Griffin Knepp
NPI 1245951094
$2,727.57
in general payments reported to CMS, 2019-2025
24 companies · $921 in 2025
The $921 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $102 · 2023: $932 · 2024: $772 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $665.65 | 2023-2025 | Ekosonic, Eluvia, Watchman Flx |
| Astrazeneca Pharmaceuticals Lp | $608.83 | 2022-2025 | Farxiga, Lokelma, Wainua |
| Novartis Pharmaceuticals Corporation | $182.73 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $156.51 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.24 | 2023-2025 | Jardiance |
| Irhythm Technologies, INC. | $119.18 | 2024 | Zio Monitor, Zio Xt Patch |
| Pfizer INC. | $92.48 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $85.58 | 2022-2023 | Verquvo |
| Novo Nordisk INC | $84.77 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $83.14 | 2023-2024 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $68.17 | 2025 | |
| Vital Connect, INC | $64.00 | 2023-2024 | Vitalpatch Rtm |
| Janssen Pharmaceuticals, INC | $62.97 | 2023-2024 | Xarelto |
| Abiomed | $58.01 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $51.44 | 2023-2024 | Evkeeza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $34.43 | 2023 | |
| Sanofi-Aventis U.S. LLC | $32.91 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.74 | 2023 | Lifevest |
| Glaxosmithkline, LLC. | $23.22 | 2025 | Shingrix, Arexvy |
| Altathera Pharmaceuticals LLC | $22.04 | 2023 | Sotalol Hydrochloride |
| Scpharmaceuticals INC. | $21.77 | 2023 | |
| Medtronic, INC. | $18.24 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.74 | 2024 | |
| Esperion Therapeutics, INC. | $14.78 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Griffin Knepp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.